Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 13, 2018

SELL
$9.16 - $13.48 $56,947 - $83,805
-6,217 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$6.3 - $13.77 $39,167 - $85,608
6,217 New
6,217 $61,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $260M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Piper Sandler & Co. Portfolio

Follow Piper Sandler & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Piper Sandler & Co., based on Form 13F filings with the SEC.

News

Stay updated on Piper Sandler & Co. with notifications on news.